A5076066556- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Restless Legs Syndrome Research
- Autism Spectrum Disorder Research
- Botulinum Toxin and Related Neurological Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Alzheimer's disease research and treatments
- Stroke Rehabilitation and Recovery
- Nuclear Receptors and Signaling
- Transcranial Magnetic Stimulation Studies
- Multiple Sclerosis Research Studies
- Protease and Inhibitor Mechanisms
- Ginkgo biloba and Cashew Applications
- Parkinson's Disease and Spinal Disorders
- Dementia and Cognitive Impairment Research
- RNA regulation and disease
- Genetic Neurodegenerative Diseases
- Balance, Gait, and Falls Prevention
- Epilepsy research and treatment
- Peripheral Neuropathies and Disorders
- Neuroinflammation and Neurodegeneration Mechanisms
- Cerebral Palsy and Movement Disorders
- Probiotics and Fermented Foods
- Peptidase Inhibition and Analysis
- Hallucinations in medical conditions
King's College London
2020-2025
King's College Hospital
2020-2025
King's College Hospital NHS Foundation Trust
2021-2025
Kings Foundation
2024
John Wiley & Sons (United States)
2024
National Hospital for Neurology and Neurosurgery
2023
University College London
2023
Innsbruck Medical University
2019
University of Sassari
2016-2019
University of Verona
2019
GLP-1 receptor agonists have neurotrophic properties in in-vitro and in-vivo models of Parkinson's disease results epidemiological studies small randomised trials suggested possible benefits for risk progression disease. We aimed to establish whether the agonist, exenatide, could slow rate did a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial at six research hospitals UK. Participants were aged 25-80 years with diagnosis disease, Hoehn Yahr stage 2·5...
To determine the diagnostic relevance of myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) in CSF seronegative cases by retrospectively analyzing consecutive time-matched 80 MOG-Ab-seronegative patients with demyelinating disease.The cohort included 44 NMOSD and related disorders 36 multiple sclerosis (MS). Two independent neurologists blinded to diagnosis analyzed MOG-Abs live cell-based immunofluorescence assay goat anti-human immunoglobulin (Ig) G (whole molecule) antibody. Sera...
Early identification of cognitive impairment in Parkinson's disease (PD) has important clinical and research implications. The aim our study was to investigate the role plasma tau phosphorylated at amino acid 181 (p-tau181) neurofilament light chain (NfL) as biomarkers cognition PD. Baseline concentrations p-tau181 NfL were measured a cohort 136 patients with PD 63 healthy controls (HC). Forty-seven followed up for 2 years. Cross-sectional longitudinal associations between baseline...
In a prospective longitudinal study with 218 Parkinson's disease (PD) patients in the discovery cohort and 84 validation cohort, we aimed to identify novel blood biomarkers predicting disability milestones PD. Through Least Absolute Shrinkage Selection Operator-Cox (Lasso-Cox) regression, developed nomogram predictive model Linear mixed-effects models, identified low level of plasma fibronectin (pFN) as one best-performing risk markers milestones. A pFN was associated short milestone-free...
Cognitive impairment is a common non-motor symptom in people with Parkinson's disease (PD) and associated to poor clinical outcomes. Currently, rivastigmine the only approved medication for PD dementia, there are no treatments available mild cognitive impairment. To advance pharmacological management of PD, it essential optimize trial design. This includes refining outcome measures, ensuring longer study durations, incorporating PD-specific assessments. Biomarkers offer valuable...
Introduction: The burden of non-motor symptoms (NMS) is a major determinant health-related quality life in Parkinson’s disease (PD), particularly at its late stage.Areas covered: stage usually defined as the period from unstable advanced to palliative stage, characterized by combination emerging treatment-resistant axial motor (freezing gait, postural instability, falls and dysphagia), well both non-dopaminergic dopaminergic NMS: cognitive decline, neuropsychiatric symptoms, aspects...
Constipation is regarded as one of the prodromal features Parkinson's disease (PD) and there emerging evidence linking gastrointestinal dysfunction cognitive impairment (CI) in PD.We explored whether constipation associated with development CI two independent cohorts de novo PD patients (n = 196 from Non-motor International Longitudinal Study [NILS] n 423 Progression Markers Initiative [PPMI] study).Constipation was clinically defined using Non-Motor Symptoms Scale (NMSS) item-21 Scales for...
It has been recently suggested that LRRK2 mutations are associated with a more benign clinical phenotype and potentially preserved cholinergic function in Parkinson's disease (PD). However, to our knowledge, no studies have tested whether the better progression observed LRRK2-PD patients is volumes of brain area, basal forebrain (BF). To address this hypothesis, here we compared BF carriers without PD respect idiopathic (iPD) controls, assessed they iPD.Thirty-one symptomatic 13 asymptomatic...
Abstract Background To date, beneficial effects of multimodal exercise programmes on Parkinson’s disease (PD) have focused motor symptoms and little attention has been paid to the potential such non-motor PD, which are now universally known as one key drivers quality life a unmet need. We aim explore clinical effectiveness ballet-based dance programme in addressing across all stages progression. Methods A randomised, single-blind, controlled trial 160 people with (Participants will be...
The identification of biomarkers that reflect worse progression nonmotor symptoms (NMS) in Parkinson's disease (PD) is currently an unmet need. main aim this study was to investigate whether cerebrospinal fluid (CSF) and serum neurofilament light (NfL), measured at baseline or longitudinally, can be used predict the NMS patients with PD.Baseline longitudinal NfL levels were CSF 392 PD 184 healthy controls from Progression Marker Initiative. assessed using several scales, including, but not...
Unexplained weight changes that occur in Parkinson's disease (PD), are often neglected and remain a poorly understood non-motor feature patients with PD. A specific 'Park-weight' phenotype low body has been described, our aim was to evaluate the clinical prognostic trajectories biomarkers of variability We evaluated weight-related 405 de novo PD 187 healthy controls (HC) over 5-year follow-up period from PPMI database. Body-weight defined as intra-individual between visits. were categorized...